Mr. Y. Mark Xu is the Co-founder, Chairman, CEO and President of Xynomic Pharmaceuticals, Inc. Mr. Xu is a successful Silicon Valley-China serial entrepreneur. During 2005-2009 Mr. Xu co-founded Bridge Labs and Pacific Biopharma Group, which merged with Pharmacyclics in 2009. Mr. Xu, through these 2 ventures, generated ~RMB 2.5 billion for co-founders and investors. During 2009-2016 Mr. Xu served as the Greater China General Manager of Trout Group, the largest investment bank and advisory firm in the US focusing exclusively on serving small-to-mid sized life sciences companies. Before 2005 Mr. Xu held progressive positions in the US at leading MNCs including Schering, McKesson (world’s largest pharmaceutical distribution company), Stanford Research Institute International, BAS, and UL. Mr. Xu holds a MBA from Stanford University, a MS in Chemistry from Purdue University and a BA in Chemistry (Magna Cum Laude) from Hanover College.
Dr. Murray Yule, MD ChB MRCP PhD
Chief Medical Officer
Murray Yule is a board certified medical oncologist who trained in the United Kingdom and Houston Texas. He gained his Phd in anticancer therapeutics at the University of Newcastle and he is a member of the Royal College of Physicans of the United Kingdom. Murray has more than seventeen years’ experience in the Pharma Industry and Biotechnology in Europe and has a broad experience of the development of early anticancer therapeutics across the globe having successfully filed multiple INDs and CTA applications exploring previously unrecognised cancer targets and published more than twenty papers in this field. Whilst working at Eisai Murray led the team that successfully achieved global market approval of eribulin for the treatment of metastatic breast cancer. As the Medical Director of Astex Therapeutics Murray was instrumental in its merger with Supergen Inc and ultimately its acquisition by Otsuka Pharmaceutical. As part of the BergenBio ASA management team Murray contributed to its successful IPO on the Norwegian exchange in 2017 followed by a further round of US investment in 2018.As a biotechnology medical officer Murray has successfully formed and driven translational and clinical collaborations with larger pharma including Novartis (small molecules leading to the development of ribociclib) and Merck (Immunoncology).
Jason Wu, PhD
Chief Operating Officer
Dr. Wu has over 20 years of working experience in pharmaceutical industry in US and China. He held senior management positions in a number of pharmaceutical companies and research institutes, including Lilly, Merck, Hutchison Medi Pharma, and Institute of Materia Medica. He has a PhD from Purdue University. Dr. Wu is an adjunct professor at the Institute of Materia Medica (IMM) of the Chinese Academy of Medical Science (CAMS). Dr. Wu has been working as a consultant for Chinese and western life sciences companies since 2012, advising clients on technology transfer, licensing, and M&A activities.
Yong Cui, PhD
Vice President of CMC
Dr. Cui has 18 years’ working experience in pharmaceutical industry in US and China. He obtained his BS and MS degrees from China Pharmaceutical University (1991 and 1994) and worked there for five years before attending Ohio State University for his PhD training (1999-2003). After graduation Dr. Cui joined Vertex Pharmaceuticals (Boston) as a formulation scientist (2003-2005). He then moved to Genentech as a formulation scientist and later moved up to become a Group Leader/Senior Scientist (2005-2013). In 2013 Dr. Cui joined Hisun-Pfizer Pharmaceuticals (Shanghai) as a Director of Formulation Development. In 2015 he joined Qilu Pharmaceuticals (Hainan) as a Vice President of R&D and Business Development of US.Dr. Cui’s experience covers both new chemical entities and generic products. He is the lead pharmaceutical scientist for two successful NDAs in the US, and has been involved in multiple interactions with the US FDA. He has been an invited expert by China FDA since 2012. Dr. Cui’s research interests include late-stage drug product development and pharmaceutical material science. He has authored or co-authored 20 publications.
Chasey Zhang,BS, MBA
Vice President of Global Strategic Sourcing
As Vice President of Global Strategic Sourcing, Ms. Zhang oversees all company operations including all countries and disciplines.
Ms. Zhang comes to Xynomic with 20+ years of company operations oversight experience including global supply chain management, alliance management, and business development, spanning across small and large pharmaceutical companies, as well as an international contract research organization (CRO). Prior to joining Xynomic Pharmaceutical, Ms. Zhang worked with several companies in senior management positions, where she had oversight responsibilities including Bristol-Myers Squibb, Clearstone Central Laboratory (acquired by LabCorp), World Courier, and an international CRO.
Ms. Zhang’s responsibilities have included oversight and management of all clinical research disciplines in Phase I-IV clinical trials. Prior to clinical research, Ms. Zhang worked as a pharmacist.
Ms. Zhang received her MBA certification from Drexel University, Post MAB certification from Rutgers University focusing on pharmaceutical management and a BS in Pharmacy & Pharmacology from The Second Military Medical University of China. Additionally, Ms. Zhang achieved her CPIM (Production and Inventory Management) certification, the globally-recognized certification for supply chain management professionals.
Dr. Bing Zhao, MD
Vice President of Clinical & Regulatory Affairs, Greater China
Dr. Zhao received his BS, MS, and MD (all majored in Oncology) from Xi’an Jiaotong University Health Science Center. He was a practicing oncologist in Xi’An, China from 1997-2007. In 2008 joined BMS in its clinical affairs department and since then has assumed increasing responsibilities as a clinical trial expert at Beijing H&J CRO International (Vice President and Director of Clinical Center), Shanghai Rundo CRO (Director of Clinical Center) ,3D-HTS (Vice President),Osmunda (Executive Vice General Manager and Director of Clinical Center)
Leigh Abbott, RN, BSN, MS
Director of Clinical Operations
As Director of Clinical Operations, Leigh Abbott oversees the strategic and operational aspects of clinical drug development for Xynomic Pharmaceuticals globally.
Ms. Abbott comes to Xynomic with 16+ years of clinical operations experience including portfolio and program management, spanning across small and large pharmaceutical companies, as well as academic research and contract research organizations. Prior to joining Xynomic Pharmaceutical, Ms. Abbott worked with several companies, where she had increasing responsibilities including BioMarin, Pfizer, Forest Labs, Sanofi, Duke Clinical Research Institute, Syneos Health, Quintiles, PPD, and Advanced Clinical.
Ms. Abbott responsibilities have included the execution of clinical trial programs, from Phase I to IV, with a recent focus on Rare Disease and Immunotherapy in bladder cancer, as well as lung. Prior to her work in clinical research, Ms. Abbott practiced as a Pediatric registered nurse and is currently licensed in North Carolina.
Ms. Abbott received her BSN in Nursing from East Carolina University, as well as her Masters. Ms. Abbott was also certified in Pediatric Oncology.
Clinical Project Manager
An experienced Clinical Research professional with expertise in Program management; Clinical Trial Management; Training; eTMF; Vendor management; Financial management; Marketing expertise; Investigator Meeting management, Regulatory regulations, as well as Risk management. Catherine has participated in multiple study phases with emphasis on Phase II and III. Additionally, Catherine is well-versed in Rare Disease studies with a Pediatric aspect. She is accomplished in Clinical Research in the US, Spain, Germany, France, Japan, Turkey, UK, and Australia.